News
The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.
Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...
In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results